 Jessica Finlay-Schultz
Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 15 | 2022 | 2059 | 1.720 |
Why?
| | Progestins | 5 | 2020 | 78 | 1.280 |
Why?
| | Receptors, Estrogen | 9 | 2020 | 392 | 1.160 |
Why?
| | Receptors, Progesterone | 6 | 2020 | 327 | 1.070 |
Why?
| | Neoplastic Stem Cells | 5 | 2020 | 343 | 0.940 |
Why?
| | Progesterone | 4 | 2017 | 243 | 0.930 |
Why?
| | Keratin-5 | 5 | 2022 | 47 | 0.760 |
Why?
| | Cell Line, Tumor | 11 | 2021 | 2913 | 0.740 |
Why?
| | Carcinoma, Lobular | 1 | 2020 | 56 | 0.680 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2020 | 92 | 0.670 |
Why?
| | Estrogens | 4 | 2017 | 337 | 0.650 |
Why?
| | RNA Polymerase III | 1 | 2017 | 31 | 0.580 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 48 | 0.470 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2017 | 1196 | 0.460 |
Why?
| | MicroRNAs | 3 | 2015 | 660 | 0.440 |
Why?
| | Receptors, Nicotinic | 2 | 2011 | 307 | 0.410 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 301 | 0.410 |
Why?
| | Mice, SCID | 5 | 2020 | 337 | 0.390 |
Why?
| | Transcription Factor AP-2 | 1 | 2011 | 81 | 0.380 |
Why?
| | Receptor, ErbB-2 | 3 | 2020 | 327 | 0.350 |
Why?
| | Mice, Inbred NOD | 4 | 2020 | 582 | 0.340 |
Why?
| | Heterografts | 2 | 2020 | 131 | 0.310 |
Why?
| | Signal Transduction | 5 | 2021 | 4809 | 0.300 |
Why?
| | Receptors, Androgen | 2 | 2021 | 137 | 0.280 |
Why?
| | Androgens | 2 | 2021 | 169 | 0.280 |
Why?
| | Schizophrenia | 1 | 2011 | 509 | 0.280 |
Why?
| | Transcriptome | 3 | 2020 | 801 | 0.250 |
Why?
| | Gene Expression Profiling | 4 | 2020 | 1642 | 0.250 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2020 | 745 | 0.230 |
Why?
| | Tamoxifen | 3 | 2020 | 199 | 0.230 |
Why?
| | Mice | 10 | 2020 | 15984 | 0.220 |
Why?
| | Keratin-17 | 1 | 2022 | 4 | 0.210 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2492 | 0.200 |
Why?
| | Thyroid Hormones | 1 | 2020 | 55 | 0.180 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 573 | 0.180 |
Why?
| | Cell Proliferation | 5 | 2021 | 2333 | 0.170 |
Why?
| | Hormone Replacement Therapy | 1 | 2020 | 81 | 0.170 |
Why?
| | Estrogen Receptor alpha | 1 | 2021 | 128 | 0.170 |
Why?
| | Hyaluronan Receptors | 3 | 2014 | 95 | 0.170 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1195 | 0.170 |
Why?
| | MCF-7 Cells | 4 | 2021 | 117 | 0.170 |
Why?
| | Up-Regulation | 2 | 2020 | 895 | 0.160 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1376 | 0.150 |
Why?
| | Female | 15 | 2022 | 64889 | 0.150 |
Why?
| | Animals | 10 | 2020 | 34345 | 0.150 |
Why?
| | beta Catenin | 1 | 2020 | 231 | 0.150 |
Why?
| | RNA, Messenger | 2 | 2019 | 2753 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 356 | 0.150 |
Why?
| | Tumor Cells, Cultured | 2 | 2017 | 902 | 0.150 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 11 | 0.150 |
Why?
| | Biomarkers, Tumor | 3 | 2022 | 1080 | 0.150 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 51 | 0.140 |
Why?
| | DNA Methylation | 2 | 2011 | 516 | 0.140 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 200 | 0.140 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 14 | 0.140 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 48 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 423 | 0.140 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 311 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 42 | 0.130 |
Why?
| | Humans | 19 | 2022 | 125131 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 332 | 0.120 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2011 | 111 | 0.120 |
Why?
| | Cisplatin | 1 | 2015 | 275 | 0.120 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 250 | 0.110 |
Why?
| | HeLa Cells | 2 | 2011 | 607 | 0.110 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.100 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 57 | 0.100 |
Why?
| | Down-Regulation | 1 | 2014 | 652 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2020 | 144 | 0.100 |
Why?
| | Apoptosis | 2 | 2017 | 2553 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 427 | 0.090 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 369 | 0.090 |
Why?
| | Genetic Vectors | 1 | 2011 | 315 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 584 | 0.080 |
Why?
| | CD146 Antigen | 2 | 2020 | 42 | 0.080 |
Why?
| | Gene Knockout Techniques | 2 | 2020 | 110 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 879 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 463 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1778 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2009 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 497 | 0.060 |
Why?
| | Vimentin | 1 | 2022 | 62 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2016 | 677 | 0.050 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2021 | 6 | 0.050 |
Why?
| | Doxorubicin | 1 | 2022 | 310 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 33 | 0.050 |
Why?
| | Mutation | 1 | 2011 | 3520 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 37 | 0.050 |
Why?
| | Adherens Junctions | 1 | 2020 | 28 | 0.040 |
Why?
| | Immunoprecipitation | 1 | 2020 | 170 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 107 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2020 | 668 | 0.040 |
Why?
| | Gene Library | 1 | 2019 | 130 | 0.040 |
Why?
| | Cadherins | 1 | 2020 | 190 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 276 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 472 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 153 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2020 | 186 | 0.040 |
Why?
| | Antigens, CD | 1 | 2020 | 466 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 574 | 0.030 |
Why?
| | Tretinoin | 1 | 2017 | 127 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2016 | 69 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 699 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2016 | 126 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2016 | 197 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2016 | 74 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 517 | 0.030 |
Why?
| | Cell Membrane | 1 | 2020 | 732 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 58 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 468 | 0.030 |
Why?
| | Adult | 1 | 2017 | 33167 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 859 | 0.030 |
Why?
| | Software | 1 | 2019 | 647 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2736 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 19 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 31 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1081 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 149 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2061 | 0.020 |
Why?
| | Glucose | 1 | 2016 | 995 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 279 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1743 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 155 | 0.020 |
Why?
| | Organ Specificity | 1 | 2011 | 288 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 243 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5348 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 785 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2577 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 557 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3823 | 0.020 |
Why?
| | Male | 2 | 2016 | 60792 | 0.010 |
Why?
|
|
Finlay-Schultz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|